On March 19, 2026, Rhythm Pharmaceuticals, Inc. announced that the FDA approved an expanded use for IMCIVREE® to treat acquired hypothalamic obesity, following positive results from a Phase 3 trial showing an average -15.8% reduction in BMI after 52 weeks.